___

• 1. Yang J, Biery DW, Singh A, et al. Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. Am J Med. 2020;133:605-612. [CrossRef]
• 2. Cengel A, Tanindi A. Myocardial infarction in the young. J Postgrad Med. 2009;55:305-313. [CrossRef]
• 3. Case BC, Abramowitz J, Shea C, et al. Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. Am J Cardiol. 2021;157:42-47. [CrossRef]
• 4. Ambroziak M, Niewczas-Wieprzowska K, Maicka A, Budaj A. Younger age of patients with myocardial infarction is associated with a higher number of relatives with a history of premature atherosclerosis. BMC Cardiovasc Disord. 2020;20:410. [CrossRef]
• 5. Yamac AH, Uysal O, Ismailoglu Z, et al. Premature Myocardial Infarction: Genetic Variations in SIRT1 Affect Disease Susceptibility. Cardiol Res Pract. 2019;2019:8921806. [CrossRef]
• 6. Gulati R, Behfar A, Narula J, et al. Acute Myocardial Infarction in Young Individuals. Mayo Clin Proc. 2020;95:136-156. [CrossRef]
• 7. Rallidis LS, Lekakis J, Panagiotakos D, et al. Long-term prognostic factors of young patients. Eur J Cardiovasc Prev Rehabil. 2008;15:567-571. [CrossRef]
• 8. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984;311:1144-1147. [CrossRef]
• 9. Tokgozoglu L, Kayikcioglu M, Ekinci B. The landscape of preventive cardiology in Turkey: Challenges and successes. Am J Prev Cardiol. 2021;6:100184. [CrossRef]
• 10. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-137. [CrossRef]
• 11. Tokgözoğlu L, Kayıkçıoğlu M, Altay S, et al. [EUROASPIRE-IV: European Society of Cardiology study of lifestyle, risk factors, and treatment approaches in patients with coronary artery disease: Data from Turkey]. Turk Kardiyol Dern Ars. 2017;45:134- 144. [CrossRef]
• 12. Erol MK, Kayıkçıoğlu M, Kılıçkap M, et al. Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study. Anatol J Cardiol. 2020;24:334-342. [CrossRef]
• 13. Dugani SB, Murad W, Damilig K, et al. Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study. Angiology. 2020;71:17-26. [CrossRef]
• 14. Setia N, Verma IC, Khan B, Arora A. Premature coronary artery disease and familial hypercholesterolemia: Need for early diagnosis and cascade screening in the Indian population. Cardiol Res Pract. 2012;2012:658526. [CrossRef]
• 15. Azar RR. Coronary heart disease and myocardial infarction in young men and women. In: Verheugt F, Dardas TF, editors. UpToDate; 2012. [CrossRef]
• 16. Kayıkçıoğlu M. How to design studies on premature myocardial infarction? Turk Kardiyol Dern Ars. 2017;45:495-497. [CrossRef]
• 17. Kayikcioglu M, Kuman Tuncel O, Tokgozoglu L. Impact of the COVID-19 pandemic in patients with a previous history of premature myocardial infarction. Am J Prev Cardiol. 2020;4:100128. [CrossRef]
• 18. Enar R. Akut miyokard infarktüsü: Trombokardiyoloji. İstanbul: Nobel Tıp Kitabevi; 2004. [CrossRef]
• 19. Erol MK, Kayıkçıoğlu M, Kılıçkap M, et al. Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. Anatol J Cardiol. 2020;24:43-53. [CrossRef]
• 20. Rubin JB, Borden WB. Coronary heart disease in young adults. Curr Atheroscler Rep. 2012;14:140-149. [CrossRef]
• 21. Abderrahman HA, Al-Abdallat IM, Idhair AK. Age threshold for proper definition of premature coronary artery disease in males. J Forensic Leg Med. 2018;58:45-49. [CrossRef]
• 22. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204-2211. [CrossRef]
• 23. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492. [CrossRef]
• 24. Nasir K, Michos ED, Rumberger JA, et al. Coronary artery calcification and family history of premature coronary heart disease: Sibling history is more strongly associated than parental history. Circulation. 2004;110:2150-2156. [CrossRef]
• 25. De Sutter J, De Bacquer D, Kotseva K, et al. Screening of family members of patients with premature coronary heart disease; results from the EUROASPIRE II family survey. Eur Heart J. 2003;24:249-257. [CrossRef]
• 26. Zhang R, Xie J, Zhou J, et al. Supravalvular Aortic Stenosis and the Risk of Premature Death Among Patients With Homozygous Familial Hypercholesterolemia. Am J Cardiol. 2021;145:58-63. [CrossRef]
• 27. Shah N, Kelly AM, Cox N, Wong C, Soon K. Myocardial Infarction in the “Young”: Risk Factors, Presentation, Management and Prognosis. Heart Lung Circ. 2016;25:955-960. [CrossRef]
• 28. Y-Hassan S. Autonomic neurocardiogenic syndrome is stonewalled by the universal definition of myocardial infarction. World J Cardiol. 2020;12:231-247. [CrossRef]
• 29. Rallidis LS, Belesi CI, Manioudaki HS, et al. Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haemost. 2003;90:272-278. [CrossRef]
• 30. Kayikçioǧlu M, Eroglu Z, Kosova B, et al. Acute myocardial infarction following an arthropod bite: Is hereditary thrombophilia a contributing factor? Blood Coagul Fibrinolysis. 2006;17:581-583. [CrossRef]
• 31. Kayikçioǧlu M, Hasdemir C, Eroǧlu Z, et al. Homozygous factor V Leiden mutation in two siblings presenting with acute myocardial infarction: A rare cause of myocardial infarction in the young. Blood Coagul Fibrinolysis. 2005;16:281-286. [CrossRef]
• 32. Kayıkçıoğlu M, Yavuzgil O, Eroğlu Z, Onay H, Ergenoğlu M, Can L. Hereditary thrombophilia (factor V R2-mutation) as a contributing factor in premature myocardial infarction associated with pregnancy. Anadolu Kardiyol Derg. 2014;14:652-654. [CrossRef]
• 33. McGill HC, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000;102:374-379. [CrossRef]
• 34. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705-2710. [CrossRef]
• 35. Weinberger I, Rotenberg Z, Fuchs J, Sagy A, Friedmann J, Agmon J. Myocardial infarction in young adults under 30 years: Risk factors and clinical course. Clin Cardiol. 1987;10:9-15. [CrossRef]
• 36. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol. 1995;26:654-661. [CrossRef]
• 37. Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol. 2003;41:521-528. [CrossRef]
• 38. Thompson CS, Pass M, Timothy T, Hung J, Egred M. Acute myocardial infarction in a young elite cyclist: A missed opportunity. BMJ Case Rep. 2019;12:e228560. [CrossRef]
• 39. Malmberg K, Båvenholm P, Hamsten A. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol. 1994;24:592-599. [CrossRef]
• 40. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. JAMA. 2018;319:1723-1725. [CrossRef]
• 41. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872. [CrossRef]
• 42. Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest. 1995;108:364-369. [CrossRef]
• 43. Breckenridge WC, Little JA, Alaupovic P, et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 1982;45:161-179. [CrossRef]
• 44. Goliasch G, Oravec S, Blessberger H, et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age). Eur J Clin Invest. 2012;42:631-636. [CrossRef]
• 45. Wiesbauer F, Blessberger H, Azar D, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (≤40 years of age). Eur Heart J. 2009;30:1073-1079. [CrossRef]
• 46. Kayikcioglu M, Tokgozoglu L, Dogan V, et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atherosclerosis. 2018;277:341-346. [CrossRef]
• 47. Singh A, Collins B, Qamar A, et al. Study of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry. Clin Cardiol. 2017;40:955-961. [CrossRef]
• 48. Pirazzi C, Håkansson L, Gustafsson C, Omerovic E, Wiklund O, Mancina RM. High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease. Appl Clin Genet. 2019;12:71-78. [CrossRef]
• 49. Kayıkçıoğlu M, Kısmalı E, Can L, Payzin S. Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic. Turk Kardiyol Dern Ars. 2014;42:599-611. [CrossRef]
• 50. Beheshti S, Madsen CM, Varbo A, Nordestgaard BG. How to Identify Familial Premature Myocardial Infarction: Comparing Approaches to Identify Familial Hypercholesterolemia. J Clin Endocrinol Metab. 2019;104:2657-2667. [CrossRef]
• 51. Kayikcioglu M. LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective. Curr Atheroscler Rep. 2021;23:15. [CrossRef]
• 52. Kayıkçıoğlu M, Uzun HG, Tetik Vardarlı A, Tokgözoğlu L. Monozygotic twins with familial hypercholesterolemia and high lipoprotein(a) levels leading to identical cardiovascular outcomes: Case report and review of the literature. Turk Kardiyol Dern Ars. 2020;48:531-538. [CrossRef]
• 53. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276:544-548. [CrossRef]
• 54. Wilcken DE, Wang XL, Greenwood J, Lynch J. Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents. J Pediatr. 1993;123:519-526. [CrossRef]
• 55. Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart J. 2019;71:184-198. [CrossRef]
• 56. Hoit BD, Gilpin EA, Henning H, et al. Myocardial infarction in young patients: An analysis by age subsets. Circulation. 1986;74:712-721. [CrossRef]
• 57. Bao W, Srinivasan SR, Wattigney WA, Berenson GS. The relation of parental cardiovascular disease to risk factors in children and young adults. The Bogalusa Heart Study. Circulation. 1995;91:365-371. [CrossRef]
• 58. Gaeta G, Barra D. Anomalie strutturali arteriose nei discendenti di soggetti con infarto precoce del miocardio [Structural arterial abnormalities in the offspring of subjects with premature myocardial infarction]. Recenti Prog Med. 2001;92:136-139. [CrossRef]
• 59. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641-2644. [CrossRef]
• 60. Trzos E, Uznańska B, Rechciński T, Krzemińska-Pakuła M, Bugała M, Kurpesa M. Myocardial infarction in young people. Cardiol J. 2009;16:307-311. [CrossRef]
• 61. Desai R, Patel U, Parekh T, et al. Nationwide Trends in Prevalent Cardiovascular Risk Factors and Diseases in Young Adults: Differences by Sex and Race and In-Hospital Outcomes. South Med J. 2020;113:311-319. [CrossRef]
• 62. Meiner V, Landsberger D, Berkman N, et al. A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet. 1991;49:443- 449. [CrossRef]
• 63. Ahmed ST, Rehman H, Akeroyd JM, et al. Premature Coronary Heart Disease in South Asians: Burden and Determinants. Curr Atheroscler Rep. 2018;20:6. [CrossRef]
• 64. Traina MI, Almahmeed W, Edris A, Murat Tuzcu E. Coronary Heart Disease in the Middle East and North Africa: Current Status and Future Goals. Curr Atheroscler Rep. 2017;19:24. [CrossRef]
• 65. Chan MY, Woo KS, Wong HB, Chia BL, Sutandar A, Tan HC. Antecedent risk factors and their control in young patients with a first myocardial infarction. Singapore Med J. 2006;47:27-30. [CrossRef]
• 66. Doughty M, Mehta R, Bruckman D, et al. Acute myocardial infarction in the young -- The University of Michigan experience. Am Heart J. 2002;143:56-62. [CrossRef]
• 67. Shojaie M, Rajpout MY, Abtahian A, Pour AE, Ghobadifar MA, Akbarzadeh A. Dehydroepiandrosterone sulfate as a risk factor for premature myocardial infarction: A comparative study. Korean J Fam Med. 2015;36:1-9. [CrossRef]
• 68. DeFilippis EM, Singh A, Divakaran S, et al. Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2018;71:2540-2551. [CrossRef]
• 69. Jain V, Goel G. Acute myocardial infarction in young newbie bodybuilder using multiple steroid and protein supplements. J Cardiol Cases. 2020;21:134-136. [CrossRef]
• 70. Rahhal A, Khir F, Adam M, Aljundi A, Mohsen MK, Al-Suwaidi J. Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: A case report. BMC Cardiovasc Disord. 2020;20:182. [CrossRef]
• 71. Corrado D, Thiene G, Cocco P, Frescura C. Non-atherosclerotic coronary artery disease and sudden death in the young. Br Heart J. 1992;68:601-607. [CrossRef]
• 72. Vrints CJM. Spontaneous coronary artery dissection. Heart. 2010;96:801-808. [CrossRef]
• 73. Ishikawa Y, Kawawa Y, Kohda E, Shimada K, Ishii T. Significance of the anatomical properties of a myocardial bridge in coronary heart disease. Circ J. 2011;75:1559- 1566. [CrossRef]
• 74. Burt JR, O’Dell MC, Yacoub B, et al. Prevalence of Abnormal Coronary Findings on Coronary Computed Tomography Angiography among Young Adults Presenting with Chest Pain. J Thorac Imaging. 2021;36:116-121. [CrossRef]
• 75. Endo M, Tomizawa Y, Nishida H, et al. Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis. J Thorac Cardiovasc Surg. 2003;125:570-577. [CrossRef]
• 76. Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clin Exp Immunol. 2011;164 Suppl 1(Suppl 1):20-22. [CrossRef]
• 77. Krittanawong C, Liu Y, Mahtta D, et al. Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. Int J Cardiol Heart Vasc. 2020;30:100634. [CrossRef]
• 78. Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol. 2009;62:584-592. [CrossRef]
• 79. Abusnina W, Shehata M, Abouzid M, Price M, Zeid F. Kounis syndrome secondary to gadolinium contrast agent. Proc (Bayl Univ Med Cent). 2019;32:253-255. [CrossRef]
• 80. Chai JT, McGrath S, Lopez B, Dworakowski R. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) masquerading as acute ST-elevation myocardial infarction with complete resolution after immunosuppressive therapy: A case report. Eur Heart J Case Rep. 2018;2:yty075. [CrossRef]
• 81. Gurgo AM, Ferri FM, Iulianella R, et al. Infarto miocardico acuto in paziente HIV-positivo in trattamento con inibitori delle proteasi [Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors]. Ital Hear J Suppl. 2001;2:1236-1239. [CrossRef]
• 82. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5:293. [CrossRef]
• 83. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet. 1994;344:1709-1710. [CrossRef]
• 84. Grassi M, Mozzini C, Albertini F, et al. Modeling premature occurrence of acute coronary syndrome with atherogenic and thrombogenic risk factors and gene markers in extended families. J Thromb Haemost. 2005;3:2238-2244. [CrossRef]
• 85. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1144. [CrossRef]
• 86. Gürgey A, Mesci L. The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey. Turk J Pediatr. 1997;39:313-315. [CrossRef]
• 87. Zhang C, Cai Y, Adachi MT, et al. Homocysteine Induces Programmed Cell Death in Human Vascular Endothelial Cells through Activation of the Unfolded Protein Response. J Biol Chem. 2001;276:35867-35874. [CrossRef]
• 88. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948- 957. [CrossRef]
• 89. Tomaiuolo R, Bellia C, Caruso A, et al. Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. J Transl Med. 2012;10:235. [CrossRef]
• 90. Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002;90:270-276. [CrossRef]
• 91. Tsukamoto K, Mani DR, Shi J, et al. Identification of apolipoprotein D as a cardioprotective gene using a mouse model of lethal atherosclerotic coronary artery disease. Proc Natl Acad Sci U S A. 2013;110:17023-17028. [CrossRef]
• 92. Hermans MPJ, Bodde MC, Jukema JW, Schalij MJ, van der Laarse A, Cobbaert CM. Low levels of apolipoprotein-CII in normotriglyceridemic patients with very premature coronary artery disease: Observations from the MISSION! Intervention study. J Clin Lipidol. 2017;11:1407-1414. [CrossRef]
• 93. Thériault S, Don-Wauchope A, Chong M, Lali R, Morrison KM, Paré G. Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: Management and considerations for cardiovascular risk. J Clin Lipidol. 2016;10:1272- 1277. [CrossRef]
• 94. Shen GQ, Li L, Girelli D, et al. An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet. 2007;81:780-791. [CrossRef]
• 95. Shen GQ, Girelli D, Li L, et al. Multi-allelic haplotype association identifies novel information different from single-SNP analysis: A new protective haplotype in the LRP8 gene is against familial and early-onset CAD and MI. Gene. 2013;521:78-81. [CrossRef]
• 96. Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: Epidemiology, pathophysiology, and management. Am J Cardiovasc Drugs. 2012;12:303-311. [CrossRef]
• 97. Martín M, González P, Reguero JJR, et al. ABCA1 polymorphisms and prognosis after myocardial infarction in young patients. Int J Cardiol. 2006;110:267-268. [CrossRef]
• 98. Zigra AM, Rallidis LS, Anastasiou G, Merkouri E, Gialeraki A. ENOS gene variants and the risk of premature myocardial infarction. Dis Markers. 2013;34:431-436. [CrossRef]
• 99. Schönfelder J, Telgmann R, Nicaud V, et al. Neutrophil elastase gene variation and coronary heart disease. Pharmacogenet Genomics. 2007;17:629-637. [CrossRef]
• 100. Bai B, Zhang M, Zhuang Y, et al. The pregnancy-associated spontaneous coronary artery dissection in a young woman with a novel missense mutation in NOTCH1: A case report. BMC Med Genet. 2020;21:119. [CrossRef]
• 101. Li Q, Brodsky JL, Conlin LK, et al. Mutations in the ABCC6 gene as a cause of generalized arterial calcification of infancy: Genotypic overlap with pseudoxanthoma elasticum. J Invest Dermatol. 2014;134:658-665. [CrossRef]
• 102. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an Inherited Disorder with Features of Coronary Artery Disease. Science. 2003;302:1578-1581. [CrossRef]
• 103. Petrovič D, Bregar D, Gužič-Salobir B, et al. Sex Difference in the Effect of ACE-DD Genotype on the Risk of Premature Myocardial Infarction. Angiology. 2004;55:155- 158. [CrossRef]
• 104. Erdos MR, Cabral WA, Tavarez UL, et al. A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome. Nat Med. 2021;27:536-545. [CrossRef]
• 105. Weir RAP, Alston AF, Ali MA. Acute myocardial infarction in Kabuki syndrome: Chance occurrence or a novel risk factor for premature atherosclerosis? Int J Cardiol. 2014;176:26-28. [CrossRef]
• 106. Fang C, Dai J, Zhang S, et al. Culprit lesion morphology in young patients with ST-segment elevated myocardial infarction: A clinical, angiographic and optical coherence tomography study. Atherosclerosis. 2019;289:94-100. [CrossRef]
• 107. Araki M, Yonetsu T, Kurihara O, et al. Age and Phenotype of Patients With Plaque Erosion. J Am Heart Assoc. 2021;10:e020691. doi:10.1161/JAHA.120.020691. [CrossRef]